CW bill text
disclosing conspicuouslyāon its website, physically in writing, and orally in person by the prescribing provider, to the patient and (if the patient is a minor) to the patientās parents or legal guardians, by means of information that includes language materially identical to each point below, that:
1. The use of puberty blocker drugs or cross-sex hormones to treat gender dysphoria
has been described as experimental by researchers and is not approved by the
Food and Drug Administration (FDA);8
2. The use of puberty blocker drugs or cross-sex hormones to treat gender dysphoria
has been recognized by medical authorities in Europe, after independent reviews, to be experimental or lacking sufficient evidence and has been substantially restricted in countries such as Sweden, Finland, Norway, and the United Kingdom;9
3. The U.S. Agency for Healthcare Research and Quality has determined, āThere is a lack of current evidence-based guidance for the care of children and adolescents who identify as transgender, particularly regarding the benefits and harms of pubertal suppression, medical affirmation with hormone therapy, and surgical affirmationā;10
4. A study spanning 5 decades of almost 5,000 transgender people who had received cross-sex hormones, regardless of treatment type, nevertheless showed a ātwo- fold increased mortality risk,ā which ādid not decrease over timeā;11
5. An article in the International Review of Psychiatry found that, according to ten different studies, the vast majority of children, 85.2%, experiencing gender dysphoria grew to become comfortable with their natal sex, and the Endocrine Society found that āthe large majority (about 85%) of prepubertal children with a childhood diagnosis did not remain GD/gender incongruent in adolescenceā;12
6. A scientific article in the Journal of Infant, Child, and Adolescent Psychotherapy concluded that āencouraging mastectomy, ovariectomy, uterine extirpation, penile disablement, tracheal shave, the prescription of hormones which are out of line with the genetic make-up of the child, or puberty blockers, are all clinical practices which run an unacceptably high risk of doing harmā;13
7. Swedenās National Board of Health and Welfare (āNBHWā) recently declared that, at least for minors, āthe risks of puberty suppressing treatment with GnRH-analogues and gender-affirming hormonal treatment currently outweigh the possible benefitsā;14
8. A systematic review of the evidence by researchers in Europe regarding natal boys concluded that there is āinsufficient evidence to determine the efficacy or safety of hormonal treatmentā and that certain hormonal interventions can potentially cause or worsen depression;15
9. One scientific study noted that an individual whose friend identifies as transgender is āmore than 70 timesā as likely to similarly identify as transgender, suggesting that many individuals may āincorrectly believe themselves to be transgender and in need of transitionā because of social factorsā;16
10. A follow-up study recently determined, āYouths with a history of mental health issues were especially likely to have taken steps to socially and medically transitionā;17
11. A study of 1,655 parental reports found that āparents tended to rate their children as worse off after transitionā and āthat parents believed gender clinicians and clinics pressured the families toward transitionā;18
12. The FDA has issued a warning that puberty blockers can lead to brain swelling and blindness;19